Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. J of Skin [Internet]. 2021 Nov. 5 [cited 2025 Apr. 18];5(6):s56. Available from: https://skin.dermsquared.com/skin/article/view/1407